According to one review of 15 studies, drinking green tea with higher amounts of EGCG for at least 12 weeks was linked to decreases in body weight and body fat ( One study in 115 women also found that taking green tea extract for 12 weeks led to significant reductions in body weight, body mass index, and belly fat ( Although scientists need to do more research in humans, some studies suggest that lemons could also promote weight loss
(PubMed) Zhang M, Robitaille L, Eintracht S, Hoffer LJ
Is this stack available in Canada
(Z)-5-(3-bromo-2-(2,3-dibromo-4,5-dimethoxybenzyl)-4,5-dimethoxybenzylidene)thiazolidine-2,4-dione increases liver glycogen storage and improves islet architecture with more beta-cells and fewer alpha-cells in dia (Z)-5-(3-bromo-4,5-dihydroxybenzylidene)thiazolidine-2,4-dione 98.82% inhibition at 0.02 mg/ml (Z)-5-(3-bromo-4,5-dimethoxybenzylidene)imidazolidine-2,4-dione 12.08% inhibition at 0.02 mg/ml (Z)-5-(3-bromo-4-hydroxy-5-methoxybenzylidene)imidazolidine-2,4-dione (Z)-5-(3-bromo-4-hydroxy-5-methoxybenzylidene)thiazolidine-2,4-dione 47.51% inhibition at 0.02 mg/ml (Z)-5-(4-(3-bromo-2-(2,3-dibromo-4,5-dimethoxybenzyl)-4,5-dimethoxyphenoxy)benzylidene)thiazolidine-2,4-dione 93.39% inhibition at 0.02 mg/ml (Z)-5-(4-hydroxy-3-methoxybenzylidene)imidazolidine-2,4-dione 28.67% inhibition at 0.02 mg/ml (Z)-5-(4-hydroxy-3-methoxybenzylidene)thiazolidine-2,4-dione ([2-bromo-4-(3-oxo-2,3-diphenylpropyl)phenyl](difluoro)methyl)phosphonic acid - 1,1'-(piperazine-1,4-diyl)bis(4-(3-(dibenzylamino)phenyl)butane-1,2,4-trione) - - 1,1'-methylenebis(2,3,6-tribromo-4,5-dimethoxybenzene) complete inhibition at 0.02 mg/ml 1,2,4-tribromo-3-[(2,3-dibromo-4,5-dimethoxyphenyl)methyl]-5,6-dimethoxybenzene 1,3-difluoro-2-[(E)-2-nitroethenyl]benzene - 50% inhibition at 0.0048 mM in absence of 2-mercaptoethanol, at 0.34 mM in presence of 1 mM 2-mercaptoethanol 1,6-dibenzyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid - 15.1% inhibition at 0.02 mg/ml 1-(1,3-benzodioxol-5-yl)-2-([1-(4-hydroxyphenyl)-1H-1,2,3,4-tetraazol-5-yl]sulfanyl)-1-ethanone 88% inhibition at 0.2 mM 1-(2,6-dihydroxy-4-methoxy-3-methylphenyl)ethanone - isolated from a methanol extract of the Antarctic lichen Stereocaulon alpinum 1-(4-fluorobenzyl)-6-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid - 36.2% inhibition at 0.02 mg/ml 1-(4-hydroxy-3-(methoxycarbonyl)benzyl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylic acid - IC50 of 8.1 mg/ml 1-benzyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid - 15.1% inhibition at 0.02 mg/ml 1-benzyl-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylic acid - 3.1% inhibition at 0.02 mg/ml 1-benzyl-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid - 0.7% inhibition at 0.02 mg/ml 1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid - 0.8% inhibition at 0.02 mg/ml 1-cyclopropyl-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylic acid - 3.5% inhibition at 0.02 mg/ml 1-cyclopropyl-N-(4-fluorobenzyl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxamide - 3.3% inhibition at 0.02 mg/ml 1-ethyl-6-methyl-3-phenyl-1H-pyrimido(5,4-e)(1,2,4)triazine-5,7-dione - covalent mode of action 1-heptyl-1H-imidazol-4-yl)-7-hydroxy-4H-chromen-4-one - 1-methoxy-4-((E)-2-nitrovinyl)benzene - 50% inhibition at 0.0045 mM in absence of 2-mercaptoethanol, at 0.27 mM in presence of 1 mM 2-mercaptoethanol 1-methyl-4-((E)-2-nitrovinyl)benzene - 50% inhibition at 0.003 mM in absence of 2-mercaptoethanol, at 0.225 mM in presence of 1 mM 2-mercaptoethanol 1-phenyl-1H-pyrrole-2,5-dione - 1-[7-methyl-3-(trifluoromethyl)naphthalen-1-yl]piperazine DES-4884, a piperazinylquinoline fragment, binds to pocket 2, which overlaps with the allosteric pocket, enzyme binding structure, crystal structure analysis (PDB ID 8G67) 15-hydroxykaur-9(11),16-dien-19-oic acid - 16alphaH,17-isovaleryloxy-ent-kauran-19-oic acid - diterpenoid isolated from Acanthopanax koreanum, 50% inhibition at 0.007 mM, noncompetitive 19alpha,24-dihydroxyurs-12-en-3-on-28-oic acid - - 2',4'-dihydroxy-1,1'-biphenyl - 2,2'-[benzene-1,4-diylbis(methanediyloxybenzene-4,1-diyl)]bis(oxoacetic acid) - - 2,2-dioxo-2,3-dihydro-2-OMEGA-16-benzo (1,2,3)oxathiazole-6-carboxylic acid (5-phenylsulfanyl-1H-benzoimidazol-2-ylmethyl)-amide - competitive, noncovalent mode of action 2,3-dibromo-1-[(2-bromo-3,4-dimethoxy-6-methylphenyl)methyl]-4,5-dimethoxybenzene 87.52% inhibition at 0.02 mg/ml 2,4-dihydroxy-6-methylbenzoic acid - 45% inhibition of PTPB1 at 0.178 mM 2,4-dimethoxy-1-((E)-2-nitrovinyl)benzene - 50% inhibition at 0.028 mM in absence of 2-mercaptoethanol, at 0.390 mM in presence of 1 mM 2-mercaptoethanol 2,5-dihydroxy-3-[7-(2-methylbenzyl)-1H-indol-3-yl]cyclohexa-2,5-diene-1,4-dione - 2,5-dihydroxy-3-[7-(3-methylbut-2-en-1-yl)-1H-indol-3-yl]cyclohexa-2,5-diene-1,4-dione - 2-((5-(naphthalen-1-yloxy)-1H-benzimidazol-1-yl)thio)-N-(thiazol-2-yl)acetamide - 2-((5-(naphthalen-2-yloxy)-1H-benzimidazol-1-yl)thio)-N-(thiazol-2-yl)acetamide - 2-((6-chloro-5-(naphthalen-2-yloxy)-1H-benzimidazol-2-yl)thio)-N-(thiazol-2-yl)acetamide - 2-((carboxycarbonyl)amino)-4,7-dihydro-5H-thieno(2,3-c)pyran-3-carboxylic acid i.e
